A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-13
DOI
10.1038/s41467-021-22980-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
- (2020) Daixi Ren et al. Molecular Cancer
- Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
- (2020) Miro E. Raeber et al. Science Translational Medicine
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential
- (2019) Emily Gobin et al. BMC CANCER
- PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
- (2018) Tricia R. Cottrell et al. CANCER JOURNAL
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
- (2018) Yuan Zhang et al. Nature Communications
- IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells
- (2018) Natasha C. Ward et al. JOURNAL OF IMMUNOLOGY
- Double-slit photoelectron interference in strong-field ionization of the neon dimer
- (2018) Maksim Kunitski et al. Nature Communications
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
- (2017) Megan Lo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
- (2017) Purnima Bhat et al. Cell Death & Disease
- Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
- (2017) Rodrigo Vazquez-Lombardi et al. Nature Communications
- Regulatory T cells control toxicity in a humanized model of IL-2 therapy
- (2017) Yan Li et al. Nature Communications
- Structural basis of a novel heterodimeric Fc for bispecific antibody production
- (2017) Hudie Wei et al. Oncotarget
- Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models
- (2017) Mansi Manchanda et al. Clinical and Translational Gastroenterology
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Site-Specific PEGylation of Therapeutic Proteins
- (2015) Jonathan Dozier et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins
- (2014) S. Dasgupta et al. JOURNAL OF IMMUNOLOGY
- Immunoexpression of Metalloproteinases 2 and 14 and TIMP-2 Inhibitor in Main Types of Primary Gastric Carcinomas and Lymph Node Metastasis
- (2014) Daniel Cordeiro Gurgel et al. PATHOLOGY & ONCOLOGY RESEARCH
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- Endocytosis and Cancer
- (2013) I. Mellman et al. Cold Spring Harbor Perspectives in Biology
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Mechanisms of Treg Suppression: Still a Long Way to Go
- (2012) Dario A. A. Vignali Frontiers in Immunology
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases
- (2011) John Puskas et al. IMMUNOLOGY
- Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast
- (2011) Yurdanur Sullu et al. PATHOLOGY RESEARCH AND PRACTICE
- IFN-γ and TNF-α secretion by CD4+ and CD8+ TCRαβ+ T-cell clones derived early after allogeneic bone marrow transplantation
- (2010) Øystein Bruserud et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer
- (2010) María Fernanda García et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor subunit CD25
- (2010) S. Letourneau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search